Non-metastatic muscle-invasive bladder cancer: the role of age in receiving treatment with curative intent

被引:5
|
作者
van Hoogstraten, Lisa M. C. [1 ,2 ]
Witjes, J. Alfred [3 ]
Meijer, Richard P. [4 ]
Ripping, Theodora M. [1 ]
Kiemeney, Lambertus A. [2 ,3 ]
Aben, Katja K. H. [1 ,2 ]
机构
[1] Netherlands Comprehens Canc Org, POB 1281, NL-6501 BG Utrecht, Netherlands
[2] Radboud Univ Nijmegen Med Ctr, Radboud Inst Hlth Sci, Nijmegen, Netherlands
[3] Radboud Univ Nijmegen Med Ctr, Dept Urol, Nijmegen, Netherlands
[4] Univ Med Ctr Utrecht, Dept Oncol Urol, Utrecht, Netherlands
关键词
muscle-invasive bladder cancer (MIBC); patient and tumour characteristics; survival; treatment; urothelial bladder carcinoma; variation in healthcare; #BladderCancer; #blcsm; LONG-TERM OUTCOMES; RADICAL CYSTECTOMY; MODALITY THERAPY; PRESERVATION; CHEMOTHERAPY; PATTERNS; SCORE;
D O I
10.1111/bju.15697
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives To evaluate which patient and tumour characteristics are associated with remaining untreated in patients with potentially curable, non-metastatic muscle-invasive bladder cancer (MIBC), and to compare survival of untreated vs treated patients with similar characteristics. Patients and methods For this cohort study, 15 047 patients diagnosed with cT2-T4aN0/xM0/x urothelial MIBC between 2005 and 2019 were identified in the Netherlands Cancer Registry. Factors associated with remaining untreated were identified using logistic regression analyses. Interhospital variation was assessed using multilevel analysis. Using a propensity score, the median overall survival (mOS) of untreated and treated patients was evaluated. Analyses were stratified by age (<75 vs >= 75 years). Results One-third of patients aged >= 75 years remained untreated; increasing age, worse performance status, worse renal function, cT4a stage and previous radiotherapy in the abdomen/pelvic area increased the odds of remaining untreated. One in 10 patients aged <75 years remained untreated; significant associations were only found for performance status, renal function and cT4a stage. Interhospital variation for remaining untreated was largest for patients aged >= 75 years, ranging from 37% to 69% (case-mix-adjusted). Irrespective of age, mOS was significantly worse for untreated patients: 6.4 months (95% confidence interval [CI] 5.1-7.3) vs 16.0 months (95% CI 13.5-19.1) for treated patients. Conclusion On average, one in five patients with non-metastatic MIBC remained untreated. Untreated patients were generally older and had a more unfavourable prognostic profile. Untreated patients had significantly worse overall survival, regardless of age. Age alone should therefore not affect treatment decision-making. Considering the large interhospital variation, a proportion of untreated patients might be wrongfully denied life-prolonging treatment.
引用
收藏
页码:764 / 775
页数:12
相关论文
共 50 条
  • [31] Chemotherapy for Muscle-Invasive Bladder Cancer
    Patrizia Trenta
    Fabio Calabrò
    Linda Cerbone
    Cora N. Sternberg
    Current Treatment Options in Oncology, 2016, 17
  • [32] Emerging intravesical drugs for the treatment of non muscle-invasive bladder cancer
    Crijnen, Jasper
    De Reijke, Theo M.
    EXPERT OPINION ON EMERGING DRUGS, 2018, 23 (02) : 135 - 147
  • [33] Chemoradiotherapy in octogenarians as primary treatment for muscle-invasive bladder cancer
    McPherson, Victor A.
    Rodrigues, George
    Bauman, Glenn
    Winquist, Eric
    Chin, Joseph
    Izawa, Jonathan
    Potvin, Kylea
    Ernst, Scott
    Venkatesan, Varagur
    Sexton, Tracy
    Ahmad, Belal
    Power, Nicholas
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2017, 11 (1-2): : 24 - 30
  • [34] Trimodality Treatment for Muscle-Invasive Bladder Cancer: An Institutional Experience
    Polineni, Praneet
    Ashack, Laura
    Kalapurakal, John
    Morgans, Alicia
    VanderWeele, David
    Kundu, Shilajit
    Hussain, Maha
    Meeks, Joshua
    Sachdev, Sean
    ADVANCES IN RADIATION ONCOLOGY, 2021, 6 (05)
  • [35] Muscle-invasive bladder cancer: evaluating treatment and survival in the National Cancer Data Base
    Smith, Angela B.
    Deal, Allison M.
    Woods, Michael E.
    Wallen, Eric M.
    Pruthi, Raj S.
    Chen, Ronald C.
    Milowsky, Matthew I.
    Nielsen, Matthew E.
    BJU INTERNATIONAL, 2014, 114 (05) : 719 - 726
  • [36] Treatment of muscle-invasive bladder cancer
    Sherif, Amir
    Jonsson, Martin N.
    Wiklund, N. Peter
    EXPERT REVIEW OF ANTICANCER THERAPY, 2007, 7 (09) : 1279 - 1283
  • [37] Chemoradiation for organ preservation in the treatment of muscle-invasive bladder cancer
    McHaffie, Derek R.
    Kruser, Tim J.
    Gaston, Kris
    Mahoney, John
    Graham, David
    Haake, Michael
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2016, 34 (06) : 271 - 278
  • [38] Outcomes by time to definitive chemoradiation treatment for patients with muscle-invasive bladder cancer
    Kotha, Nikhil V.
    Kumar, Abhishek
    Nelson, Tyler J.
    Qiao, Edmund M.
    Qian, Alex S.
    Voora, Rohith S.
    Mckay, Rana R.
    Rose, Brent S.
    Stewart, Tyler F.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2022, 40 (06) : 274.e1 - 274.e6
  • [39] Follow-up surveillance of muscle-invasive urinary bladder cancer after curative treatment
    Schulz, G. B.
    Stief, C. G.
    Schlenker, B.
    UROLOGE, 2019, 58 (09): : 1093 - 1106
  • [40] Muscle-invasive bladder cancer
    Buchler, Jakob
    Gschwend, Juergen E.
    Retz, Margitta
    Schmid, Sebastian C.
    UROLOGE, 2021, 60 (06): : 769 - 775